
Protagonist Therapeutics (PTGX) P/E Ratio
P/E Ratio as of Jun 13, 2025: 74.10
Average65.88
Median64.24
Minimum58.49
Maximum74.10
74.10
Past Month+15.72 (26.93%)
The P/E ratio for Protagonist Therapeutics (PTGX) is 74.10 as of Jun 13, 2025. This represents a increase of 304.03% compared to its 12-month average P/E ratio of 18.34. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Protagonist Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Protagonist Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Protagonist Therapeutics to industry peers.
Protagonist Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Protagonist Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Protagonist Therapeutics to industry peers.
Protagonist Therapeutics (PTGX) P/E Ratio Insights
See Protagonist Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares
Protagonist Therapeutics (PTGX) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $50.15 | 65.93 |
May 1, 2025 | $44.99 | 10.70 |
Apr 1, 2025 | $46.88 | 11.15 |
Mar 3, 2025 | $38.50 | 9.15 |
Feb 3, 2025 | $37.20 | 13.96 |
Jan 2, 2025 | $38.98 | 14.62 |
Protagonist Therapeutics (PTGX) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | 74.10 | +411.74% |
2024 | 14.48 | -265.11% |
2023 | -8.77 | +114.43% |
2022 | -4.09 | -67.69% |
2021 | -12.66 | +25.72% |
2020 | -10.07 | — |
FAQs About Protagonist Therapeutics (PTGX) P/E ratio
The latest P/E ratio of Protagonist Therapeutics (PTGX) is 74.10, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Protagonist Therapeutics’s last 12-month average P/E ratio is 18.34, compared to its current P/E ratio of 74.10. This reflects a increase of 304.03%.
Protagonist Therapeutics’s current P/E ratio of 74.10 is higher than its last 12-month average P/E of 18.34. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Protagonist Therapeutics’s average P/E ratio over the last 3 years is 2.63. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Protagonist Therapeutics’s average P/E ratio over the last 5 years is -3.33. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.